Search Results - "Sonsire Fernández-Castillo"
-
1
OMV-based vaccine formulations against Shiga toxin producing Escherichia coli strains are both protective in mice and immunogenic in calves
Published in Human vaccines & immunotherapeutics (01-01-2018)“…Strains of Shiga toxin-producing Escherichia coli (STEC) can cause the severe Hemolytic Uremic Syndrome (HUS). Shiga toxins are protein toxins that bind and…”
Get full text
Journal Article -
2
A Bordetella pertussis proteoliposome induces protection in mice without affecting the immunogenicity of diphtheria and tetanus toxoids in a trivalent formulation
Published in Clinical and experimental vaccine research (Seoul) (01-07-2016)“…In this study, a formulation of Bordetella pertussis proteoliposome (PLBp), diphtheria, and tetanus toxoids and alum (DT-PLBp) was evaluated as a trivalent…”
Get full text
Journal Article -
3
Vacunas contra rotavirus: estado actual y tendencias futuras
Published in Vaccimonitor (01-12-2016)“…Antes de la introducción de las vacunas contra el rotavirus en 2006, este patógeno era considerado la principal causa de gastroenteritis entre los niños…”
Get full text
Journal Article -
4
Reactividad de sueros de ratones inmunizados con vesículas de membrana externa derivadas de Salmonella entérica
Published in Vaccimonitor (01-02-2021)“…La fiebre tifoidea causada por Salmonella Paratyphi A (fiebre paratifoidea) es indistinguible de la producida por Salmonella Typhi y el grado de incidencia ha…”
Get full text
Journal Article -
5
Condiciones de adsorción de un candidato vacunal basado en vesículas de membrana externa derivada de Salmonella Paratyphi A en adyuvantes de aluminio
Published in Vaccimonitor (01-07-2019)“…La capacidad inmunoestimuladora de la mayoría de las vacunas es potenciada mediante la adsorción en adyuvantes que contienen aluminio. Variando las condiciones…”
Get full text
Journal Article -
6
Repeat-dose and local tolerance toxicity of SARS-CoV-2 FINLAY-FR-02 vaccine candidate in Sprague Dawley rats
Published in Toxicology (Amsterdam) (15-04-2022)“…This study evaluates safety of FINLAY-FR-02, a vaccine candidate against SARS-CoV-2 based on the recombinant receptor binding domain conjugated to tetanus…”
Get full text
Journal Article -
7
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children
Published in International journal of infectious diseases (01-01-2023)“…•FINLAY-FR-2 conjugate vaccine is safe and immunogenic in children 3-18 years old.•The third dose with FINLAY-FR-1A (dimer receptor binding domain vaccine)…”
Get full text
Journal Article -
8
Estandarización de un ELISA para la cuantificación de anticuerpos IgG contra vesículas de membrana externa de Salmonella Paratyphi A
Published in Vaccimonitor (01-12-2018)“…Salmonella Paratyphi A es un patógeno exclusivo de humanos, siendo la segunda causa más común de fiebre entérica en el sudeste asiático. Recientemente la…”
Get full text
Journal Article -
9
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
Published in Lancet Regional Health - Americas (Online) (01-02-2023)“…SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity,…”
Get full text
Journal Article -
10
Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2–11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study
Published in Lancet Regional Health - Americas (Online) (01-06-2024)“…Increased pediatric COVID-19 occurrence due to the SARS-CoV-2 Omicron variant has raised concerns about the effectiveness of existing vaccines. The protection…”
Get full text
Journal Article -
11
Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2–11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population studyResearch in context
Published in Lancet Regional Health - Americas (Online) (01-06-2024)“…Background: Increased pediatric COVID-19 occurrence due to the SARS-CoV-2 Omicron variant has raised concerns about the effectiveness of existing vaccines. The…”
Get full text
Journal Article -
12
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trialResearch in context
Published in Lancet Regional Health - Americas (Online) (01-02-2023)“…Background: SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated to tetanus toxoid). Phases 1/2 clinical trials demonstrated high…”
Get full text
Journal Article -
13
Diseño, desarrollo y evaluación preclínica de SOBERANA®02: una vacuna cubana contra COVID-19
Published in Anales de la Academia de Ciencias de Cuba (01-03-2023)Get full text
Journal Article -
14
Generation of a murine monoclonal antibody to capsular polysaccharide Vi from Salmonella Typhi
Published in Vaccimonitor (01-11-2015)“…The conventional hybridoma technology has enabled the development of monoclonal antibodies (Mabs) against many antigens. Mabs have several applications in the…”
Get full text
Journal Article -
15
Synthesis of oligosaccharides from terminal B. pertussis LPS pentasaccharide and definition of the minimal epitope recognized by anti-pertussis antibodies
Published in Glycoconjugate journal (01-10-2024)“…Pertussis vaccines have been very effective in controlling whooping-cough epidemics but are ineffective in controlling circulation in older children and…”
Get full text
Journal Article -
16
Evaluación preclínica y clínica de SOBERANA® 01. Candidato vacunal contra la COVID-19
Published in Anales de la Academia de Ciencias de Cuba (01-12-2023)“…RESUMEN Introducción: SOBERANA® 01 se desarrolló en el Instituto Finlay de Vacunas para el enfrentamiento a la epidemia causada por el virus SARS-CoV-2. Este…”
Get full text
Journal Article -
17
Obtaining of a rapid diagnostic test for Cholera, based on latex particles coupled with a monoclonal antibody against Vibrio cholera O1 lipopolysaccharide
Published in Vaccimonitor (01-08-2015)“…Cholera is an acute contagious intestinal disease caused by ingestion of food or water contaminated with O1 and O139 serotypes of the bacterium Vibrio…”
Get full text
Journal Article -
18
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
Published in Vaccine (29-07-2022)“…SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we report…”
Get full text
Journal Article -
19
Advances in the characterization of a proteol iposome derived from Mycobacterium bovis BCG as vaccine candidate against tuberculosis
Published in Vaccimonitor (01-12-2014)“…Despite efforts to eradicate tuberculosis (TB) worldwide, this remains a serious health problem. The Bacillus Calmette-Guerin (BCG), the only available vaccine…”
Get full text
Journal Article -
20
Obtención de un anticuerpo monoclonal murino que reconoce al polisacárido capsular Vi de Salmonella Typhi
Published in Vaccimonitor (01-08-2015)“…La tecnología clásica del hibridoma permitió el desarrollo de anticuerpos monoclonales (AcM) contra una inmensa variedad de antígenos, los cuales tienen…”
Get full text
Journal Article